ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 0893 • ACR Convergence 2023

    Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model

    Trine Jorgensen and Lindsey Han, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…
  • Abstract Number: 1665 • ACR Convergence 2023

    Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis

    Hanlin Yin1, Oliver Distler2, Bin Li3, Qingran Yan4 and Liangjing Lu1, 1Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Shanghai institute of immunology, Shanghai, China, 4Department of Rheumatology, Renji Hospital, Shanghai Jiaotong Univeisty School of medcine, Shanghai, China

    Background/Purpose: Type I interferon (IFN-1) signature is a hallmark of patients with systemic sclerosis (SSc). However, its significance in clinical stratification and contribution to deterioration…
  • Abstract Number: 0091 • ACR Convergence 2023

    Impaired X-Chromosome Inactivation Maintenance in T Cells Is Associated with Features of Reduced Disease Severity in a Toll-Like Receptor 7-Driven Model of Systemic Autoimmunity

    Nikhil Jiwrajka1, Zowie Searcy2, Claudia Lovell2, Natalie Toothacre2, Katherine Forsyth2 and Montserrat Anguera2, 1Divison of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, Phildelphia, PA, 2Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA

    Background/Purpose: Many systemic autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren's syndrome, and systemic sclerosis are highly female-biased. Although these diseases are more prevalent…
  • Abstract Number: 0894 • ACR Convergence 2023

    The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light

    Jie An1, Xizhang Sun1, Rayan Najjar1, Connie Zhao1, Paul Kong2, Stephanie Weaver2, Amanda Koehne2, Matt Fitzgibbon2 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Fred Hutchinson Cancer Center, Seattle, WA

    Background/Purpose: SLE patients characteristically have a prominent type I interferon (IFN-I) signature in lesional and non-lesional skin. We recently demonstrated that, following a single exposure…
  • Abstract Number: 1708 • ACR Convergence 2023

    In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity

    Yan Du1, Evan Hsu2, Kailey Brodeur3, Meng Liu4, Mindy Lo5, Craig Platt3 and Pui Lee5, 1Harvard medical school, Boston, MA, 2Wesleyan University, Newton, MA, 3Boston Children's Hospital, Boston, MA, 4Southern Medical University, Boston, MA, 5Division of Immunology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Systemic autoimmunity can be driven by monogenic or polygenic risk variants. We aimed to characterize the genetic basis of disease in a family with…
  • Abstract Number: 0093 • ACR Convergence 2023

    Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients

    Ye Cao1, Takanori Sasaki2, Richard Ainsworth3, Kim Taylor4, Nunzio Bottini5, Mehreen Elahee6, Edy Kim7, Francesco Boin3 and Deepak Rao7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, CA, 6University of Pittsburgh Medical Center, Pittsburgh, PA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…
  • Abstract Number: 0910 • ACR Convergence 2023

    17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice

    Kathryn Sullivan, Yong Wang, Winn Chatham, John Mountz and Hui-chen Hsu, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: While systemic lupus erythematosus (SLE) disproportionally affects women versus men, elevation in estradiol (E2) alone is not sufficient to promote the development of autoantibody…
  • Abstract Number: 1922 • ACR Convergence 2023

    Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

    Charline Vauchy1, Maxime Desmarets1, Paul Bastard2, Anne Puel2, Pascale Richard3, Jean Laurent Casanova2, Pierre Tiberghien3, Eric Toussirot4 and Francois Aubin5, 1INSERM CIC-1431, Besançon, France, 2IHU Imagine, AP-HP Necker, Paris, France, 3Etablissement Français du Sang, St. Denis, France, 4University Hospital of Besancon, Besançon, France, 5Dermatology, University Hospital of Besancon, Besançon, France

    Background/Purpose: Hidradenitis suppurativa (HS) is a multifactorial auto-inflammatory disorder with a prevalence of 1% in North American and European populations. HS may be associated with…
  • Abstract Number: 023 • 2023 Pediatric Rheumatology Symposium

    Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle

    Lauren Covert1, Joseph Prinz2, Hailee Patel3, Jeffrey Dvergsten4 and George Truskey3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Department of Biostatistics and Bioinformatics, Durham, NC, 3Duke University, Department of Biomedical Engineering, Durham, NC, 4Duke University Hospital, Durham, NC

    Background/Purpose: Genetic studies of new-onset juvenile dermatomyositis (JDM) exhibit elevation of Type 1 interferons (IFN 1) IFNα and IFNβ in blood, skin, and muscle. To…
  • Abstract Number: 075 • 2023 Pediatric Rheumatology Symposium

    Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome

    Claudia Bracaglia1, Manuela Pardeo1, Giulia Marucci2, Simona Riccio2, Francesco Quagliarella3, Ivan Caiello2, Giusi Prencipe2, Pietro Merli3, Franco Locatelli3 and Fabrizio De Benedetti1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, 3Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy

    Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of different rheumatic diseases, particularly of systemic juvenile idiopathic arthritis (sJIA).Methods: We report the case of…
  • Abstract Number: 080 • 2023 Pediatric Rheumatology Symposium

    Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)

    Yoel Levinsky1, Oded Scheuerman2, Rotem Tal3, Gil Amarilyo3 and Liora Harel3, 1Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 2Pediatric B department, Schneider children's medical center of Israel, Petach Tikva, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel

    Background/Purpose: Interferonopathies are a recently recognized group of genetic syndromes associated with uncontrolled activation of interferon. PRAAS (proteasome-associated autoinflammatory syndromes) is an interferonopathy caused by…
  • Abstract Number: 0361 • ACR Convergence 2022

    Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus

    Tina Baker1, Sharifian Hoda2, Paul Newcombe1, Mark Lazarus1, Madhu Ramaswamy3, Nicola Ferrari1, Daniel Muthas2, Hussein Al-Mossawi1, Raj Tummala3, Eric F. Morand4, Richard A. Furie5, Edward Vital6 and Philip Brohawn3, 1AstraZeneca, Cambridge, United Kingdom, 2AstraZeneca, Gothenburg, Sweden, 3AstraZeneca, Gaithersburg, MD, 4Monash University, Melbourne, Australia, 5Northwell Health, Great Neck, NY, 6University of Leeds, Leeds, England, United Kingdom

    Background/Purpose: Anifrolumab is a monoclonal antibody to IFN-α receptor 1 that inhibits type I IFN signaling. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab…
  • Abstract Number: 0974 • ACR Convergence 2022

    Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers

    Lucy Marie Carter1, Zoe Wigston1, Jack Arnold1 and Philip Laws2, 1University of Leeds, Leeds, United Kingdom, 2Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
  • Abstract Number: 1936 • ACR Convergence 2022

    A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype

    Sara Alehashemi1, Adriana Almeida de Jesus2, Jonas Johannes Papendorf3, Farzana Bhuyan4, Kat Uss5, Anvitha Metpally6, Bin Lin7, Sophia Park8, Thais C.L. Moura9, Renata R Dias9, Mayra B. Dorna9, Katia Kozu9, Adriana Sallum9, Lucia M. A. Campos9, Gijs Santen10, Jesper Kers10, Onno Teng11, Karin Palmblad12, Tom Huizinga10, Frédéric Ebstein13, Elke Krüger13 and Raphaela Goldbach-Mansky14, 1NIH/NIAID/TADS, Clarksville, MD, 2NIAID, NIH, Silver Spring, MD, 3Institut für Medizinische Biochemie und Molekularbiologie, Universitätsmedizin Greifswald, Greifswald, Germany, 4National Institutes of Health, Bethesda, MD, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6NIAID, NIH, Bethesda, MD, 7NIH, Bethesda, MD, 8NIAID, Bethesda, MD, 9Children's Hospital of the University of São Paulo, São Paulo, Brazil, 10Leiden University Medical Center, Leiden, Netherlands, 11Leiden University Medical Center, Leiderdorp, Netherlands, 12Karolinska University Hospital, Stockholm, Sweden, 13Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, 14NIH/NIAID, Potomac, MD

    Background/Purpose: Homozygote (HM)/compound heterozygote (CH) and digenic (DG) mutations in proteasome subunits cause the autoinflammatory syndrome CANDLE, or proteasome-associated autoinflammatory syndrome (PRAAS). Inflammation is mediated…
  • Abstract Number: 0556 • ACR Convergence 2022

    Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response

    Zachary Peters1, Lindsay Mendyka1, Sicong Shan1, Angelique Cortez1, William Rigby2, Christopher Burns1, Randolph Noelle3 and Sladjana Skopelja-Gardner1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth Hitchcock Medical Center, Lebanon, PA, 3Geisel School of Medicine at Dartmouth, Lebanon, NH

    Background/Purpose: Most lupus patients chronically exhibit higher IFN-I scores in the skin, peripheral blood, and kidneys that is exacerbated by ultraviolet (UV) light. In normal…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology